©PDC*line
PLL Therapeutics obtains authorization to start phase I/II trial in Australia for patients with Amyotrophic Lateral Sclerosis (ALS)
©AdobeStock
PLL Therapeutics appoints Dr. Souad Kechairi as chief medical officer
Courtesy of Dr. Souad Kechairi
Duhn Therapeutics, launched by Landmark BioVentures, signs global license agreement with OM Pharma to further advance clinical-stage, lipid-based cancer immunotherapy
©Courtesy of OM Pharma
Provepharm launches Blumyne™ surgical dye in UK
(C) Adobe stock
Banook Group deploys growth strategy with acquisitions of Keosys and B.Research
© Banook Group
SK pharmteco et ART-TG accueillent le premier symposium international Momentum in Cell & Gene Therapy en France
Canva copyright-free photo
People living with pulmonary hypertension call for better psychological support in the absence of awareness of this severe disease
Ferrer Germany appoints Olaf Gerber as country manager
Ferrer reports top-line results from phase III ADORE study in ALS
(c) Ferrer